LAG3 and neoplasm: Moreover, other factors, including tertiary lymphoid tissues (TLTs) characterized by ectopic lymphoid tissues that drive antigen-specific immune responses at sites of chronic inflammation, microsatellite status, tumor mutational burden (TMB), ICs, T-cell immunoglobulin and mucin-domain containing-3 [TIM-3], and lymphocyte activation gene-3 [LAG3], the inhibitory receptor expressed on T-cells or other immune cells, all influence treatment efficacy [28,29,30].